Stockscreener 앱 받기
26.05
0.61%
-0.16
시간 외 거래:
25.69
-0.36
-1.38%
전일 마감가:
$26.21
열려 있는:
$26.23
하루 거래량:
925.46K
Relative Volume:
1.49
시가총액:
$1.45B
수익:
$2.50M
순이익/손실:
$-131.12M
주가수익비율:
-9.1625
EPS:
-2.8431
순현금흐름:
$-112.73M
1주 성능:
+15.67%
1개월 성능:
-14.37%
6개월 성능:
-17.90%
1년 성능:
-1.14%
1일 변동 폭
$25.42
$27.79
1주일 범위
$21.95
$29.91
52주 변동 폭
$21.95
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
명칭
Maze Therapeutics Inc
전화
(650) 850-5070
주소
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
26.05 | 1.45B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Buy |
| 2026-03-10 | 개시 | Mizuho | Outperform |
| 2025-12-04 | 개시 | Wells Fargo | Overweight |
| 2025-11-14 | 개시 | Raymond James | Outperform |
| 2025-09-02 | 개시 | BTIG Research | Buy |
| 2025-07-23 | 개시 | H.C. Wainwright | Buy |
| 2025-07-08 | 개시 | Wedbush | Outperform |
모두보기
Maze Therapeutics Inc 주식(MAZE)의 최신 뉴스
Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now? - Yahoo Finance
Maze Therapeutics, Inc. (MAZE) stock price, news, quote and history - Yahoo Finance Australia
Maze Therapeutics, Inc. (MAZE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Maze Therapeutics Price Target Maintained With a $46.00/Share by BTIG - Moomoo
Maze Therapeutics Initiated at Buy by Citigroup - Moomoo
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday - Benzinga
A Quick Look at Today's Ratings for Maze Therapeutics(MAZE.US), With a Forecast Between $46 to $110 - Moomoo
Maze Therapeutics Shares Rise 2.9% After CIBC Initiates Coverage - Yahoo Finance
Why is Maze Therapeutics stock climbing today? By Investing.com - Investing.com Canada
Correction: Citigroup Initiates Maze Therapeutics at Buy With $50 Price Target - Yahoo Finance
BTIG Initiates Maze Therapeutics at Buy With $50 Price Target - Yahoo Finance
The Surprise That Sent Vertex — And Its Chief Rival — Soaring - Investor's Business Daily
Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech - Barron's
Truist Financial Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $64 - Moomoo
BTIG reiterates Buy rating on Maze Therapeutics, $46 price target - TradingView
Maze Therapeutics stock hits 52-week low at 22.44 USD By Investing.com - Investing.com India
Maze Therapeutics stock hits 52-week low at 22.44 USD - Investing.com
Maze Therapeutics, Inc. (MAZE) Stock Analysis: A 166.83% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Maze Therapeutics (MAZE) Slips 1.30% to $23.91 as Shares Drift Toward Key SupportRunaway Gap - careplusvn.com
Maze Therapeutics at H.C. Wainwright conference: pipeline nears key tests By Investing.com - Investing.com Canada
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000 - The Motley Fool
Maze Therapeutics at Citi summit: early data, bigger tests ahead By Investing.com - Investing.com South Africa
Wells Fargo Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com Australia
Maze Therapeutics at Wells Fargo conference: pipeline gains pace By Investing.com - Investing.com Nigeria
Maze Therapeutics (MAZE) Institutional Ownership 2026 - MarketBeat
Maze therapeutics president, R&D & CMO, sells $254,501 in shares - Investing.com India
Maze Therapeutics (MAZE) R&D chief exits direct stake - Stock Titan
Maze Therapeutics CSBO Atul Dandekar Disposes of 6,434 Shares at $25.81-$27.12 (NASDAQ: MAZE) - Kalkine Media
Don't Ignore The Insider Selling In Maze Therapeutics - simplywall.st
Maze Therapeutics (MAZE) Stock Analysis Report | Financials & Insights - Benzinga
MAZE News | MAZE THERAPEUTICS INC (NASDAQ:MAZE) - ChartMill
Courtney Phillips Executes 11,000 Zero-Cost Options in Maze Therapeutics (NASDAQ: MAZE) on September 1, 2026 - Kalkine Media
Maze Therapeutics CSBO Atul Dandekar Sells 6,434 Shares to Cover RSU Tax Withholding - Kalkine Media
Maze Therapeutics (NASDAQ: MAZE) officer lines up new stock sale after recent 10b5-1 trades - Stock Titan
Maze Therapeutics Chief Executive Officer Sold Shares Worth Over $593K - TradingView
Maze Therapeutics (MAZE) legal chief sells stock for taxes - Stock Titan
Insider at Maze Therapeutics (MAZE) sells shares to cover taxes - Stock Titan
Maze Therapeutics (MAZE) CEO sells shares to cover taxes - Stock Titan
Maze Therapeutics (MAZE) R&D chief sells shares to cover RSU taxes - Stock Titan
Maze Therapeutics, Inc. Common Stock (NASDAQ: MAZE) Stock Price, News & Analysis - Kalkine
Maze Therapeutics Officer Courtney Phillips Reports RSU Vesting and Stock Settlement - Kalkine Media
Maze Therapeutics CEO Jason V Coloma Reports RSU Vesting and Trust Share Sales in Form 4 Filing - Kalkine Media
RSU vesting gives Maze Therapeutics (MAZE) exec 12,500 shares - Stock Titan
Maze Therapeutics (MAZE) CEO gets 50K shares, trims stake via trust sales - Stock Titan
Rule-based stock plan leads Maze Therapeutics (MAZE) exec to sell shares and log 20,000 RSUs - stocktitan.net
Maze Therapeutics (MAZE) legal chief gets 11,000 shares - Stock Titan
Officer plans to sell up to $623K in Maze Therapeutics (MAZE) stock from vested RSUs - Stock Titan
Maze Therapeutics to Participate in Three Upcoming Investor Conferences - markets.businessinsider.com
Maze Therapeutics (MAZE) executive plans new stock sale after recent trades - Stock Titan
Maze Therapeutics Inc (MAZE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):